TB immunodiagnosis in context of global disease care and control by Mark D Perkins
ORAL PRESENTATION Open Access
TB immunodiagnosis in context of global disease
care and control
Mark D Perkins
From Immunodiagnosis of Tuberculosis: New Questions, New Tools
Virginia, VA, USA. 21-23 September 2008
The persistence of the tuberculosis epidemic depends
upon ongoing transmission from undetected and
untreated cases. Unfortunately, though high cure rates
have now been achieved in many countries, globally
case detection is delayed and incomplete, both because
diagnostic testing is relatively hard to access, and
because it relies on inadequate technologies. Fewer than
half of all TB cases are thought to be detectable by
microscopy even if all suspects were appropriately
examined. Delays in diagnosis are common, and patients
are often ill for 4 to 8 months before they are detected
and treated. During this delay, morbidity accrues and
transmission to household and community contacts
continues.
To improve TB case detection, new technologies are
needed which are more rapid than culture and that are
either highly sensitive, such as new-generation molecu-
lar tests, or simple enough to use that they can be
widely available, even if imperfectly sensitive. Lateral
flow immunoassays are among the simplest clinical diag-
nostic tests to perform, and are routinely used outside
laboratory settings to detect conditions such as preg-
nancy and malaria. The availability of a well-performing
seroimmunodiagnostic test for tuberculosis on a lateral
flow platform could vastly simplify case detection and
improve TB care and control if testing. Such assays are
relatively simple to develop, and in fact more than two
dozen such tests are marketed in the private sector, pri-
marily in Asia. Unfortunately, of the many commer-
cially-manufactured tests currently available to detect
anti-TB antibody responses, none are accurate enough
to be recommended for use in disease control programs.
A limited number of TB antigens, however, have been
explored for their diagnostic potential, and the on-going
discovery of new antigens may allow development of
improved serodiagnostic tests. To this end, FIND is col-
laborating with a team of scientists to interrogate the
entire TB proteome to identify antigen candidates for
new tests.
In collaboration with Felgner and colleagues (Antigen
Discovery, Inc.), microarrays containing the entire TB
proteome have been created using a high-throughput
cloning and expression system. At PHRI, Gennaro and
colleagues have used these arrays to screen serum sam-
ples from TB patients with and without concomitant
HIV infection, and appropriate controls. A subset of the
most promising antigens will be taken forward for
development of an optimized seroimmunodiagnostic.
The goal is a test that is either sensitive enough to
exclude TB in test-negative symptomatic individuals, or
specific enough to direct therapy in those who are
positive.
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